In FBC, if human epidermal growth factor receptor 2 (HER-2) was negative, ER+/PR− and ER+/PR+ breast cancer would be categorized as luminal B subtype and luminal A subtype, respectively, with different prognosis. The gene discussed is PGR; the disease is breast carcinoma.